Monvia Limited Prolongs IPO Deadline to July 8, 2026, Outlines $19.4 Million Capital Deployment Plan

Monvia's Detailed $17.5 Million IPO Capital Allocation Strategy

Following the IPO closing date extension, Monvia Limited disclosed its comprehensive capital allocation plan. The company aims to raise $17.5 million through its IPO, supplemented by approximately $1.896 million in cash as of the original prospectus date, 24 June 2026. This results in total available funds of $19.396 million, which the board has allocated across strategic initiatives to bolster growth and market positioning.

The largest allocation, $12.5 million or 64.45% of total funds, will be used to redeem Series B Preference Shares immediately upon ASX admission. Remaining funds will support business expansion, operational efficiency, and R&D efforts. By providing detailed fund usage information, Monvia offers prospective investors clear insight into its post-listing capital deployment plans.

Series B Preference Shares Redemption and Capital Structure Streamlining

Redeeming Series B Preference Shares is a key component of Monvia's capital strategy at ASX admission. Allocating $12.5 million to this redemption underscores the company’s focus on simplifying its capital structure as it becomes publicly listed. This action removes preference capital held by earlier investors, streamlining the shareholder base and reducing future dividend obligations to preference shareholders. The redemption will occur immediately upon listing, ensuring a simplified capital structure from the first day of trading.

The prospectus details the terms of the Series B Preference Shares in Section 10.3, highlighting the specific rights and obligations being extinguished. Allocating over 64% of raised capital to this purpose signals Monvia's commitment to providing public investors with a clear and straightforward capital framework, a common practice for companies transitioning from private to public status.

$1.7 Million Investment in International Expansion and Sales & Marketing

Monvia has earmarked $1.7 million, or 8.77% of total funds, for sales, marketing, and international expansion within 12 months of ASX admission. This allocation demonstrates management’s confidence in expanding the company’s market reach beyond its current geography. The international growth focus indicates significant opportunities in untapped markets that Monvia intends to pursue post-listing.

Investing in sales and marketing early in the public phase aims to accelerate customer acquisition and brand visibility, critical for gaining momentum with institutional investors and analysts. The international emphasis reflects belief in the global appeal of Monvia’s products and services, positioning the company to capitalize on competitive advantages abroad.

General Working Capital and Commitment to Research & Development

Monvia has allocated $3.810335 million, or 19.64% of available funds, for general working capital within 12 months of listing. This allocation is divided among three operational categories: 50% for research and development, 22% for staff costs, and 28% for administrative expenses including regulatory, legal, and compliance costs.

The substantial R&D investment highlights Monvia’s focus on continuous innovation to sustain competitive advantage. Staff cost allocation reflects the labor-intensive nature of software and technology operations requiring skilled personnel. Administrative expenses cover the governance and compliance obligations of a public company. Collectively, these allocations demonstrate Monvia’s plan to balance product development with scaling organizational infrastructure.

IPO Closing Date Extension and Revised Timeline

Monvia extended its IPO closing date from 29 June 2026 to 5:00pm WST on Wednesday, 8 July 2026, allowing nine additional days for investor participation. This extension aligns with common practices to maximize subscription and investor demand. The supplementary prospectus lodged on 8 July 2026 confirms the extension and provides updated details on fund usage and expenditure.

The updated IPO timetable schedules share issuance on 16 July 2026, dispatch of holding statements on 17 July 2026, and ASX trading commencement on 24 July 2026. These dates are indicative and may change at the discretion of Monvia and its Joint Lead Managers. The extended closing date enhances investor certainty and supports a smoother transition to public trading.

IPO Expenses and Cost Management

Monvia has allocated $1.385665 million, or 7.14% of total funds, to cover IPO-related expenses including Joint Lead Manager fees, prospectus preparation, ASIC lodgement, ASX application, legal, and other professional fees. Approximately $329,335 of these costs were paid by 24 June 2026, with the remaining $1.056 million expected as the IPO progresses.

Allocating about 7% of capital to IPO costs aligns with market norms for small to mid-sized offerings. These one-time expenses are funded from IPO proceeds, preserving existing cash reserves. Transparent disclosure of these costs assures investors of efficient IPO management and maximizes capital available for strategic initiatives.

Loan Facility and Operational Cash Flow Management

Monvia referenced a $6 million loan facility outstanding as of the prospectus date, excluding interest. The board plans to repay this facility using operational cash flow rather than IPO proceeds, with repayment due by 30 June 2027. This approach reflects confidence in the company’s ability to generate sufficient cash from ongoing operations.

Retaining the loan facility preserves liquidity for strategic investments in sales, marketing, international expansion, and R&D during the first year post-listing. The board’s confidence is supported by inquiries confirming ongoing profitability up to the prospectus date.

Revenue Generation and Working Capital Adequacy

Monvia’s update confirms that its operations and ordinary business expenses are primarily funded through customer-generated revenue, indicating an established, revenue-generating business model rather than a pre-revenue stage. This operational maturity underpins the company’s working capital planning and debt repayment strategy.

The board concludes that IPO proceeds combined with operational revenues will sufficiently fund company operations for at least 12 months post-listing, reducing the likelihood of immediate recapitalization. However, the company acknowledges potential future financing needs, with associated risks detailed in Section 8.4(a) of the prospectus.

Regulatory Compliance and ASX Approval Process

The supplementary prospectus was issued to extend the IPO closing date and provide additional ASX-required information on fund usage and expenditure. It was prepared following a directors' resolution and signed by Chairman Russell Baskerville on behalf of Monvia. All directors consented to the lodgement, indicating unanimous board support.

The supplementary prospectus complements the replacement prospectus dated 24 June 2026. Neither ASIC nor ASX assumes responsibility for its contents, consistent with regulatory norms. The document states that the extension and updates do not materially alter the investment proposition disclosed previously, ensuring investor confidence.